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Abstract The prion protein (PrP) has been proposed to display
sequence and structural similarities to membrane-anchored
signal peptidases [Glockshuber et al. (1998) FEBS Lett. 426,
291^296]. We have investigated the role of Tyr-128 and His-177
in the proteolytic fragmentation of murine PrP by mutating these
residues to Phe and Leu, respectively, and expressing the
resultant mutants in the human neuroblastoma SH-SY5Y. Both
PrP-Y128F and PrP-H177L were expressed at the cell surface
as glycosyl-phosphatidylinositol-anchored forms and were lo-
calised in detergent-insoluble membrane domains similar to wild
type PrP. Following deglycosylation, the 19 kDa proteolytic
fragment PrP-II was present in cells expressing either mutant,
indicating that Tyr-128 and His-177 are not involved in the
proteolytic fragmentation of PrP.
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1. Introduction
Prion diseases are a group of neurodegenerative diseases
that include Creutzfeldt^Jakob disease, Gerstmann^Strauss-
ler^Scheinker syndrome, fatal familial insomnia and kuru in
humans, scrapie in sheep and bovine spongiform encephalop-
athy in cattle. These diseases are caused by a conformational
change in the normal cellular isoform of the prion protein
(PrPC) to the scrapie isoform PrPSc [1,2]. Human PrPC is
synthesised as a protein of 254 amino acids which undergoes
a variety of post-translational modi¢cations including glyco-
sylation, glycosyl-phosphatidylinositol (GPI) anchor addition,
and proteolysis [3]. The GPI anchor predisposes PrPC to clus-
ter in detergent-insoluble, cholesterol- and glycosphingolipid-
rich membrane domains (DIGs) in the plasma membrane
[4,5]. It is within DIGs that the fate of PrPC is determined
[6]. Either PrPC undergoes a conformational change from a
form with predominantly K-helical secondary structure to one
with mainly L-sheet forming PrPSc, or it is proteolytically
cleaved within the central hydrophobic, neurotoxic region
(residues 106^126) generating an N-terminally truncated frag-
ment termed PrP-II, which is then further metabolised [7^10].
Recombinant murine PrP (residues 23^231) expressed in Es-
cherichia coli was also found to be sensitive to proteolytic
degradation, with cleavage occurring after residues 116, 118
and 120 [11,12]. Prolonged incubation at acidic pH resulted in
complete degradation of the N-terminal fragment (residues
23^120) while the C-terminal fragment was resistant to further
metabolism.
Recently it was proposed that PrPC has structural similar-
ities to membrane-anchored signal peptidases, and that be-
cause of these similarities the proteolytic fragmentation of
PrPC may be due to autocatalysis [13]. Murine PrP (residues
121^217) is 22.7% identical and 40.9% similar to residues 49^
137 of a catalytic subunit of rat signal peptidase which is a
member of a larger clan (clan SF) of bacterial and eukaryote
peptidases that have a Ser/Lys or Ser/His catalytic dyad
[14,15]. Members of this clan include the E. coli umuDP pro-
tein involved in SOS mutagenesis, the bacterial LexA protein
involved in the control of DNA repair, as well as signal pep-
tidases and mitochondrial/chloroplast leader peptidases which
remove N-terminal peptides from secretory and organelle pro-
teins, respectively. LexA and umuDP both undergo autocatal-
ysis ; in the case of LexA this cleavage inactivates it, whereas
umuDP is activated [16]. Members of clan SF have a Ser
residue which acts as the nucleophile, and either a Lys or
His as the general base to increase the nucleophilicity of the
active site Ser. In the Pseudomonas 7A glutaminase-asparagi-
nase and Thermoplasma acidophilum 20S proteasome a Thr
replaces the Ser [14]. Comparison of PrP with members of
clan SF has shown that His-177 aligns with the conserved
His/Lys, while in place of the Ser is another hydroxylated
residue, Tyr-128 [13]. Both of these residues are completely
conserved in PrP from all species.
We have investigated the hypothesis proposed by Glock-
shuber et al. [13] that Tyr-128 and His-177 are involved in
the autocatalytic fragmentation of murine PrP by mutating
these residues to Phe and Leu, respectively. The resulting mu-
tant proteins have been expressed in the human neuroblasto-
ma SH-SY5Y cell line, which lacks detectable levels of human
PrP. The Y128F and H177L PrP mutants were both expressed
at the cell-surface as glycosylated, GPI-anchored forms indis-
tinguishable from wild type PrP and were localised in DIGs.
In addition, both mutants underwent proteolytic fragmenta-
tion identical to that observed for the wild type protein, in-
dicating that Tyr-128 and His-177 are not involved in this
process.
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2. Materials and methods
2.1. Generation of PrP mutants
Murine PrP cDNA with the 3F4 epitope tag (a gift from Dr D.A.
Harris, Washington University, St. Louis, MO, USA) was subcloned
using EcoRV into the mammalian expression vector pIRESneo (Clon-
tech, California, USA). Directed mutagenesis was performed using the
Stratagene Quick Change Mutagenesis Kit according to the manufac-
turer’s instructions. The primers used to generate PrP-Y128F and
PrP-H177L were 5P-GCT CCC CAG CAT CAA GCC AAG GCC-
3P and 5P-CAT ATT GAC GCA GTC GAG CAC GAA GTT GTT
CTG G-3P, respectively. The mutants generated were con¢rmed by
DNA sequencing.
2.2. Cell culture and transfection
SH-SY5Y cells were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 10% foetal bovine serum and 50 U/ml pen-
icillin-streptomycin. Cells were maintained in 5% CO2/95% O2 at
37‡C. Cells at mid-con£uency were electroporated with either wild
type DNA or one of the mutant sequences (30 Wg cDNA in 0.8 ml)
and then transferred to 80 cm2 £asks. Stably expressing transfectants
were selected 48 h post-transfection with 0.5 mg/ml Geneticin. Cell
lysates were prepared from one 175 cm2 £ask of cells which was
washed twice with phosphate-bu¡ered saline (PBS) and then scraped
into 25 ml PBS. Following centrifugation at 1000Ug for 3 min, the
cell pellet was resuspended in 0.3 ml lysis bu¡er (50 mM Tris^HCl,
pH 7.6, 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% Triton
X-100, 10 mM EDTA and protease inhibitor cocktail [Sigma, Poole,
UK]) and incubated at room temperature for 30 min. The resulting
lysates were clari¢ed by centrifugation at 13 000Ug for 5 min.
2.3. SDS-PAGE and Western blot analysis
Samples were mixed with an equal volume of reducing electropho-
resis sample bu¡er (125 mM Tris^HCl, pH 6.8, 2% (w/v) SDS, 20%
(v/v) glycerol, 100 mM dithiothreitol, bromophenol blue) and boiled
for 3 min. Proteins were resolved by SDS polyacrylamide gel electro-
phoresis using a 15% acrylamide gel and transferred to Immobilon P
poly(vinylidene di£uoride) (PVDF) membranes [17]. The membranes
were blocked by incubation in PBS containing 0.1% (v/v) Tween 20,
5% (w/v) dried milk powder, and 2% (w/v) bovine serum albumin
overnight at 4‡C. All primary and secondary antibody incubations
were performed in the same bu¡er as that used for blocking. PrP
was detected using antibody 3F4 which recognises residues 109^112
[18] or antibody 6H4 which recognises residues 144^152 [19]. Bound
antibody was detected using peroxidase-conjugated secondary anti-
bodies in conjunction with an enhanced chemiluminescence detection
system (Amersham Life Sciences, Little Chalfont, Buckinghamshire,
UK). Protein was quanti¢ed using bicinchoninic acid [20] in a micro-
titre plate assay with bovine serum albumin as standard.
2.4. Enzyme treatments
For release of PrP with Bacillus thuringiensis phosphatidylinositol-
speci¢c phospholipase C (PI-PLC) (a gift from Dr M.G. Low, Co-
lumbia University, New York, NY, USA), cells were rinsed three
times with Opti-MEM and then incubated for 3 h at room temper-
ature in Opti-MEM containing 0.2 U/ml PI-PLC. The medium was
then harvested, concentrated by methanol precipitation and the result-
ing pellet resuspended in lysis bu¡er. For digestion of PrP with pro-
teinase K, cell lysates were incubated for 15 min at 37‡C with 3.3 Wg/
ml proteinase K. The reaction was terminated by adding an equal
volume of boiling reducing sample bu¡er and boiling for a further
3 min. For deglycosylation of PrP with peptide N-glycosidase F
(PNGase F), cell lysates were made 20 mM with respect to sodium
phosphate, pH 7.6, 50 mM with respect to EDTA, 5% (w/v) with
respect to SDS and 5% (v/v) with respect to 2-mercaptoethanol. Sam-
ples were boiled for 5 min, diluted 5-fold with 1.25% (v/v) Triton
X-100 and incubated at 37‡C for 16 h with 1 U PNGase F.
2.5. Isolation of DIGs
Cells were homogenised by 20 strokes in a Dounce homogeniser at
4‡C in 0.5 ml MES-bu¡ered saline (MBS), pH 6.5, containing 1%
Triton X-100. Samples were mixed with an equal volume of 80%
sucrose in MBS containing 1% Triton X-100 and a 1 ml aliquot
injected under a 4 ml 5^30% sucrose gradient in MBS containing
0.5% Triton X-100. DIGs were isolated by centrifugation at
100 000Ug for 18 h at 4‡C [21]. After centrifugation the gradients
were fractionated into 0.5 ml aliquots and the pellet resuspended in
0.5 ml MBS.
3. Results
Residues Tyr-128 and His-177 in murine PrP were mutated
to Phe and Leu, respectively. Like the wild type PrP, the
resulting mutants PrP-Y128F and PrP-H177L were epitopi-
cally tagged by replacement of Leu-108 and Val-111 with
methionines which allows for their recognition by the spe-
cies-speci¢c antibody 3F4 [18]. Murine PrPs tagged with the
3F4 epitope have been used extensively in cell biological stud-
ies [22^24]. Each of the constructs was stably expressed in the
human neuroblastoma SH-SY5Y [25], which lacks detectable
levels of endogenous human PrP (Fig. 1). Cell lysate and
medium samples from untransfected and transfected SH-
SY5Y cells were then examined for the expression of PrP by
Western blot analysis (Fig. 1). No endogenous human PrP
was detected in untransfected SH-SY5Y cells. Wild type PrP
and both of the mutants appeared as di¡use bands of 29^35
kDa, detectable only in the cell lysate and not in the medium.
To demonstrate that the wild type and mutant forms of PrP
were GPI-anchored and present at the cell surface, intact cells
were incubated with B. thuringiensis PI-PLC (Fig. 1). In the
absence of PI-PLC, all of the PrP in the wild type and the two
mutants was detected in the cell lysate, whereas in the pres-
ence of PI-PLC the majority of wild type PrP and virtually all
of PrP-Y128F and PrP-H177L were detected in the medium,
indicating that all three were present on the cell surface in a
GPI-anchored form. PrPC, like other GPI-anchored proteins,
is enriched in DIGs [6]. The distribution of wild type PrP and
the two mutants in DIGs within the SH-SY5Y cells was de-
termined by buoyant sucrose density gradient centrifugation.
Analysis of the resulting gradient fractions revealed that both
PrP-Y128F and PrP-H177L, like wild type PrP, were present
primarily in fractions 4^6 of the sucrose gradients (Fig. 2).
The majority of £otillin, a well-characterised marker protein
of DIGs from neuronal tissue [26,27], was also present in
fractions 4^6, demonstrating that these fractions were en-
Fig. 1. Phospholipase C cleavage of wild type and mutant PrPs.
Cell lysates (L, 10 Wg of protein) and medium (M, 10 Wg of protein)
samples from either non-transfected SH-SY5Y cells (SH, lane 1) or
cells expressing either wild type PrP (WT, lanes 2^5), PrP-Y128F
(lanes 6^9) or PrP-H177L (lanes 10^13) were incubated as indicated
in the absence or presence of B. thuringiensis PI-PLC before electro-
phoresis on a 15% acrylamide gel and then transfer to PVDF mem-
brane. PrP was detected with antibody 3F4 as described in Section
2.
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riched in DIGs. Consequently, neither mutation had a¡ected
the association of PrP with DIGs.
In order to assess whether the mutations had caused the
acquisition of PrPSc-like properties, the proteinase K sensitiv-
ity of PrP-Y128F and PrP-H177L was assessed (Fig. 3). Fol-
lowing incubation with proteinase K, both wild type PrP and
the two mutants were completely digested, with no evidence
for a protease-resistant core indicative of PrPSc.
To characterise the proteolytic fragmentation of the wild
type and mutant PrPs, cell lysates were digested with PNGase
F in order to cleave the N-linked oligosaccharides from PrP.
After deglycosylation, full-length PrP (27 kDa) and a 19 kDa
proteolytic fragment, analogous to PrP-II observed in Syrian
hamster brains [7], were detected in lysates from cells express-
ing wild type PrP using antibody 6H4 (Fig. 4). PrP-II is not
recognised by antibody 3F4 and consequently represents a C-
terminal fragment of PrP with its N-terminus lying in the
region between the epitopes for the 3F4 and 6H4 antibodies
[10]. PrP-II was also detected, to a similar extent as cells ex-
pressing wild type PrP, in cells expressing either PrP-Y128F or
PrP-H177L, indicating that these mutations had no detectable
e¡ect on the proteolytic fragmentation of PrP when expressed
in the SH-SY5Y cells.
4. Discussion
Mutation of the active site Ser and Lys/His residues to Ala
in members of clan SF inactivates these proteins [28^31], and
in the case of Lex A and umuDP prevents autocatalysis [16].
However, replacement of the active site Ser in E. coli LexA or
B. subtilis signal peptidase with either Thr or Cys does not
result in abolition of protease activity [29,30], indicating that
other nucleophilic side chains can substitute for the hydroxyl
group on Ser. Numerous proteases are known which have
either a nucleophilic Ser or Cys involved in catalysis, while
a limited number of examples use Thr [32]. To our knowledge
no protease has to date been identi¢ed that has a catalytic
Tyr, although the possibility of such enzymes existing cannot
be ruled out, with PrP being the forerunner of a protease
family with a novel catalytic mechanism.
In order to examine whether Tyr-128 and His-177 in PrP
correspond to the active site Ser and Lys/His residues in mem-
bers of clan SF and are involved in autocatalysis, thus testing
the hypothesis of Glockshuber et al. [13], we mutated these
Fig. 2. Localisation of wild type and mutant PrPs in DIGs. SH-
SY5Y cells expressing either (a and d) wild type PrP, (b) PrP-
Y128F or (c) PrP-H177L were homogenised and the resulting ho-
mogenate injected under a 5^30% sucrose gradient. DIGs were sepa-
rated from the solubilised protein by centrifugation as described in
Section 2. The resulting sucrose gradients were fractionated from
the top (fraction 9) to the bottom (fraction 1) and the pellet (P)
was resuspended in MBS. Fractions were then electrophoresed on a
15% acrylamide gel, transferred to PVDF and either (a, b, c) PrP
detected with antibody 3F4 or (d) £otillin detected with an anti-£o-
tillin antibody (Transduction Laboratories, Lexington, KY, USA).
Fig. 3. Proteinase K digestion of wild type and mutant PrP. Cell ly-
sates (10 Wg of protein) from SH-SY5Y cells expressing either wild
type PrP (WT, lanes 1 and 2), PrP-Y128F (lanes 3 and 4) or PrP-
H177L (lanes 5 and 6) were incubated as indicated in the absence
or presence of proteinase K before electrophoresis on a 15% acryl-
amide gel and then transfer to PVDF membrane. PrP was detected
with antibody 3F4 as described in Section 2.
Fig. 4. Deglycosylation of wild type and mutant PrP. Cell lysates
(10 Wg of protein) from SH-SY5Y cells expressing either wild type
PrP (WT, lanes 1 and 2), PrP-Y128F (lanes 3 and 4) or PrP-H177L
(lanes 5 and 6) were incubated as indicated in the absence or pres-
ence of PNGase F before electrophoreses on a 15% acrylamide gel
and then transfer to PVDF membrane. PrP was detected with anti-
body 6H4 as described in Section 2.
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residues to Phe and Leu, respectively. The resulting mutants,
when expressed in SH-SY5Y cells, were glycosylated, GPI-
anchored and targeted to DIGs in the plasma membrane in
an identical manner to wild type PrP. The mutant forms of
PrP were still proteolytically processed to the 18 kDa frag-
ment PrP-II, thus indicating that the observed proteolytic
fragmentation is not an autocatalytic process involving Tyr-
128 and His-177. Whether PrP has other, yet to be identi¢ed,
proteolytic activity awaits to be determined, but the availabil-
ity of the Tyr-128 and His-177 mutants should aid in this
search. Alternatively, PrP may be catalytically inactive as a
protease, with the three-dimensional structural similarities to
the signal peptidases re£ecting the fact that PrP binds to pep-
tides or proteins without cleaving them. This would be anal-
ogous to the binding of peptides with C-terminal basic resi-
dues to the catalytically inert form of trypsin, anhydrotrypsin
[33].
Given the current interest in PrP due to its role in trans-
missible spongiform encephalopathies such as new variant
CreutzfeldtPJakob disease in humans, and our limited under-
standing of the physiological roles of the protein, further in-
vestigation on the structural similarities between PrP and sig-
nal peptidases appear warranted.
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